・Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Rämet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B; RENOIR Clinical Trial Group. N Engl J Med. 2023 Apr 5. DOI: 10.1056/NEJMoa2213836
・Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
Kiyosue A, Dunn JP, Cui X, Hickey A, Hirase T, Imaoka T, Heine RJ. Diabetes Obes Metab. 2023 Apr;25(4):1056-1067. DOI: 10.1111/dom.14952
・One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.
Shinkai M, Ebisawa M, Fukushima Y, Takeuchi S, Okada H, Tokiyo T, Hayashi N, Takikawa M, Colice G, Almqvist G.J Asthma. 2023 Mar;60(3):616-624. DOI: 10.1080/02770903.2022.2082309
・Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
Ishizuka T, Menzies-Gow A, Okada H, Fukushima Y, Hayashi N, Colice G, Ponnarambil S, Hunter G, Odajima H, Ebisawa M. Allergol Int. 2023 Jan;72(1):82-88. DOI: 10.1016/j.alit.2022.07.004
・Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. N Engl J Med. 2022 Nov 24;387(21):1923-1934. DOI: 10.1056/NEJMoa2210645
・Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. N Engl J Med. 2022 Jul 21;387(3):205-216. DOI: 10.1056/NEJMoa2206038
・A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Kidney Int. 2022 Jan;101(1):174-184. DOI: 10.1016/j.kint.2021.09.005
・Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. DOI: 10.1016/S2213-8587(21)00174-1
・Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Eur Heart J. 2021 Mar 31;42(13):1216-1227. DOI: 10.1093/eurheartj/ehab094
・Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. N Engl J Med. 2021 Mar 18;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
・Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. N Engl J Med. 2020 Oct 8;383(15):1436-1446. DOI: 10.1056/NEJMoa2024816
・Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N; PIONEER 10 Investigators. Lancet Diabetes Endocrinol. 2020 May;8(5):392-406. DOI: 10.1016/S2213-8587(20)30074-7
・Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y; PIONEER 9 investigators. Lancet Diabetes Endocrinol. 2020 May;8(5):377-391. DOI: 10.1016/S2213-8587(20)30075-9
・Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P.Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2993-3002. DOI: 10.2147/COPD.S220861
・Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2979-2991. DOI: 10.2147/COPD.S220850
・Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators. Diabetes Care. 2019 Dec;42(12):2262-2271. DOI: 10.2337/dc19-0898
・Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. N Engl J Med. 2019 Sep 12;381(11):1023-1034. DOI: 10.1056/NEJMoa1905248
・PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M; PIONEER 1 Investigators. Diabetes Care. 2019 Sep;42(9):1724-1732. DOI: 10.2337/dc19-0749
・Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial.
Nomura A, Tanigawa T, Muto T, Oga T, Fukushima Y, Kiyosue A, Miyazaki M, Hida E, Satake K.J Med Internet Res. 2019 Apr 26;21(4):e13520. DOI: 10.2196/13520
・Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. N Engl J Med. 2018 Sep 6;379(10):913-923. DOI: 10.1056/NEJMoa1716197
・Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M.J Gastroenterol. 2018 Jul;53(7):834-844. DOI: 10.1007/s00535-017-1417-z
・Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
Kiyosue A, Seino Y, Nishijima K, Bosch-Traberg H, Kaku K. J Diabetes Investig. 2018 Jul;9(4):831-839. DOI: 10.1111/jdi.12759
・Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, Kiyosue A. Diabetes Obes Metab. 2018 May;20(5):1202-1212. DOI: 10.1111/dom.13218
・Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
Fukushima Y, Nakatani Y, Ide Y, Sekino H, St Rose E, Siddiqui S, Maes A, Reisner C. Int J Chron Obstruct Pulmon Dis. 2018 Apr 13;13:1187-1194. DOI: 10.2147/COPD.S159246
・Association of baseline plasma des-acyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia.
Togawa K, Matsuzaki J, Kobayakawa M, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, Naito Y, Hayakawa T, Kamiya T, Andoh T, Yoshida H, Tokura Y, Nagata H, Mori M, Kato K, Hosoda H, Takebayashi T, Miura S, Uemura N, Joh T, Hibi T, Suzuki H.J Gastroenterol Hepatol. 2016 Feb;31(2):334-41.
・Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.
Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, Bosch-Traberg H, Seino Y.J Diabetes Investig. 2016 Jan;7(1):76-84.
・Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. N Engl J Med. 2014 Sep 25;371(13):1198-207.
・Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study.
Suzuki H, Matsuzaki J, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, Naito Y, Hayakawa T, Kamiya T, Andoh T, Yoshida H, Tokura Y, Nagata H, Kobayakawa M, Mori M, Kato K, Hosoda H, Takebayashi T, Miura S, Uemura N, Joh T, Hibi T, Tack J; Rikkunshito study group. Neurogastroenterol Motil. 2014 Jul;26(7):950-61. DOI: 10.1111/jgh.13074
・Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study.
Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang CE, Chiba T, Hori M, Fukushima Y, Kim HS, Chang CY, Date M; LAVENDER Study Group. Gut. 2014 Jul;63(7):1061-8. DOI: 10.1136/gutjnl-2013-304722
・High frequency of overlap between functional dyspepsia and overactive bladder.
Matsuzaki J, Suzuki H, Fukushima Y, Hirata K, Fukuhara S, Okada S, Hibi T. Neurogastroenterol Motil. 2012 Sep;24(9):821-7. DOI: 10.1111/j.1365-2982.2012.01939.x
・Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.
Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T. J Neurogastroenterol Motil. 2012 Jul;18(3):317-23. DOI: 10.5056/jnm.2012.18.3.317
・福嶋康之 他 日本人成人気管支喘息患者におけるテルブタリンとサルブタモールの単回投与の有用性の比較 アレルギー・免疫 2011 Sep;18 (9):1360-1368
※下から6本の論文は、東京駅センタービルクリニックで責任医師として参加したもの